Evidence map›Paper›PMID 41411059›Full record

ArticleJCI insight2026

CD8+ T cells cross-restricted by HLA-B*57 and HLA-E*01 recognize HIV Gag with different functional profiles.

Kevin J Maroney, Michael A Rose, Allisa K Oman, Abha Chopra, Hua-Shiuan Hsieh, Zerufael Derza, Rachel Waterworth, Mark A Brockman, Spyros A Kalams, Anju Bansal and 1 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kevin J MaroneyDepartment of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Michael A RoseDepartment of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Allisa K OmanDepartment of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abha ChopraCentre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Perth, Western Australia, Australia.
Hua-Shiuan HsiehFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Zerufael DerzaFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Rachel WaterworthFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
Spyros A KalamsDepartment of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Anju BansalDepartment of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Paul A GoepfertDepartment of Medicine, Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Funding

Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
VIROLOGY COREP30AI054999 · NIAID · VANDERBILT UNIVERSITY · PI HAAS, DAVID W · 2003 to 2011
$10.3M
Project 3P01AI191224 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI J. Victor Garcia-Martinez · 2025 to 2026
$8.4M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
PARTNERS/FENWAY/SHATTUCK CENTER FOR AIDS RESEARCHP30AI042851 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2000 to 2003
$5.7M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
TCR GENE USAGE AND QUANTITATION OF HIV SPECIFIC CTLR01AI039966 · NIAID · VANDERBILT UNIVERSITY · PI KALAMS, SPYROS A · 1997 to 2006
$3.2M
Defining the biological relevance of HIV specific HLA-E restricted CD8 T cell responsesR01AI162168 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BANSAL, ANJU, GOEPFERT, PAUL A. · 2021 to 2024
$3.0M
NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS P01 AI191224NIAID NIH HHS P30 AI042851NIAID NIH HHS P30 AI054999NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI039966NIAID NIH HHS R01 AI162168NIAID NIH HHS T32 AI007051NIDA NIH HHS 75N95020D00005ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Few HIV-specific epitopes restricted by non-classical HLA-E have been described, and even less is known about the functional profile of responding CD8+ T cells (CD8s). This study evaluates the functional characteristics of CD8s targeting the Gag epitope KF11 (KAFSPEVIPMF) restricted by either HLA-E (E-CD8s) or HLA-B57 (B57-CD8s). CD8s from 8 people with HIV (PWH) were cocultured with KF11 peptide presented by cell lines expressing HLA-B*57:01, HLA-E*01:01, or HLA-E*01:03. CD8 responses were analyzed using single-cell RNA and TCR sequencing. Supernatants were also assessed for soluble protein profiling. HLA-I multimers were developed to identify CD8s restricted by HLA-B57 and/or HLA-E ex vivo. B57-CD8s secreted higher levels of cytotoxic cytokines such as IFN-γ, whereas E-CD8s produced more chemotactic cytokines, including RANTES, CXCL10 (IP-10), and IL-27, findings that were corroborated through single-cell RNA sequencing. TCR clonotypes stimulated by KF11 were cross-restricted by HLA-B*57 and HLA-E*01:03 as demonstrated by in vitro T cell reporter assays and ex vivo multimer screening. Ex vivo CD8s were singly restricted by HLA-B57 and HLA-E, with dual restriction only observed in PWH with lower viral load. These findings demonstrate that certain HIV-specific CD8s in PWH exhibit dual restriction by HLA-B*57 and HLA-E*01:03, leading to functionally distinct immune responses depending on the restricting allele(s).

Indexed as

CD8-Positive T-Lymphocytesgag Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class IHIV InfectionsHLA-B AntigensAdultEpitopes, T-LymphocyteFemaleHIV-1HLA-E AntigensHumansMaleMiddle AgedEpitopes, T-Lymphocytegag Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class IHLA-B*57:01 antigenHLA-B57 antigenHLA-B AntigensHLA-E AntigensAdaptive immunityAIDS/HIVAntigenInfectious diseaseT cell receptor

Identifiers

PMID41411059
PMCPMC12893105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.